Quarterly ResultAug 12, 2026, 04:06 PM
ArriVent BioPharma Q2 Net Loss $93.2M; Firmonertinib Phase 3 Data 2H 2026
AI Summary
ArriVent BioPharma reported its second-quarter 2026 financial results, showing a net loss of $93.2 million for the six months ended June 30, 2026. The company highlighted significant pipeline progress, including the anticipated topline global pivotal Phase 3 data for firmonertinib in 2H 2026. Additionally, ARR-217 advanced to Phase 1b dose optimization, and the first patient dosing for ARR-002 is expected in Q3 2026. ArriVent maintains a strong financial position with $373.1 million in cash and investments, projected to fund operations into 2028.
Key Highlights
- Topline Phase 3 data for firmonertinib in EGFR exon 20 insertion mutant NSCLC expected 2H 2026.
- ARR-217, a CDH17 targeted ADC, advanced to Phase 1b dose optimization for GI malignancies.
- First patient dosing for ARR-002 in ovarian and endometrial cancers expected Q3 2026.
- Cash and investments totaled $373.1 million as of June 30, 2026.
- Cash and investments are expected to fund operations into 2028.
- Net loss for the six months ended June 30, 2026, was $93.2 million.
- Research and development expenses were $80.0 million for the six months ended June 30, 2026.
Price Impact
More from AVBP